Flecainide sebagai Antiaritmia untuk Fibrilasi Atrium dan Aritmia Lainnya
DOI:
https://doi.org/10.55175/cdk.v51i4.948Keywords:
Antiarrhythmia, atrial fibrillation, flecainide, rhythm controlAbstract
Atrial fibrillation (AF) is one of the most common arrhythmias globally, and its prevalence is projected to increase, including in Indonesia. AF progression is related to lower quality of life and less responsive to therapy or even becomes irreversible. The progression of AF is significantly slower with the rhythm control strategy than with the rate control strategy alone. The options for therapy in Indonesia are limited to amiodarone and propafenone. Amiodarone is one of the most common drugs prescribed for AF rhythm control, but associated with multiple organ toxicities, thus increasing the risk of multiple side effects, especially on long-term usage, potentially leading to drug discontinuation. Flecainide is an antiarrhythmia with a favourable effectiveness and safety profile, especially for AF management, used for acute cardioversion, long-term rhythm control, and as a therapeutic modality for AF with preexcitation syndrome. Flecainide is a potential drug to address the unmet needs of amiodarone as a long-term management for AF.
Downloads
References
Desai DS, Hajouli S. Arrhythmias. [Updated 2022 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558923/
Chow GV, Maine JE, Fleg JL. Epidemiology of arrhythmias and conduction disorders in older adults. Clin Geriatr Med. 2012; 28: 539-53.
PERKI. Pedoman tata laksana fibrilasi atrium nonvalvular. Edisi kedua. Jakarta: Trans Medical Internasional; 2018.
Kornej J, Borschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century. Circ Res. 2020; 127: 4-20.
Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke. 2010; 41: 2884-8.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020; 42: 373-498.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-104.
Chevalier P. The place of antiarrhythmic drugs and rhythm control in the treatment of atrial fibrillation. Eur Cardiol Rev. 2009; 36-40.
BPOM. Cek Produk BPOM [Internet]. [cited 30 Jun 2023]; Available from: https://cekbpom.pom.go.id/
Pannone L, D’Angelo G, Gulletta S, Falasconi G, Brugliera L, Frontera A, et al. Amiodarone in ventricular arrhythmias: still a valuable resource?. Rev Cardiovasc Med. 2021; 22: 1383-92.
Epstein AE, Olshansky B, Naccarelli GV, Kennedy Jr JI, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016; 129: 468-75.
Tumewu A. Kontroversi penggunaan amiodaron untuk terapi atrial fibrillation pada penderita sindrom Wolff-Parkinson-White. CDK. 2018; 45: 629-32.
Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015; 7: 76-85.
Vincent R. Drugs in modern resuscitation. Brit J Anaesth. 1997; 79: 188-97.
Tambocor – Drugs@FDA: FDA-approved drugs [internet]. [cited 2023 May 23]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018830
Echt DS, Liebson PR, Mitchell B, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo – the cardiac arrhythmia suppression trial. N Engl J Med. 1991; 324: 781-8.
Tambocor [package insert]. Bedfordview: iNova; 2020.
Echt DS, Ruskin JN. Use of flecainide for the treatment of atrial fibrillation. Am J Cardiol. 2020; 125: 1123-33.
Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992; 70: 69-72.
Markey GC, Salter N, Ryan J. Intravenous flecainide for emergency department management of acute atrial fibrillation. 2018; 54: 320-7.
Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003; 87: 121-8.
Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the ‘pill-in-the-pocket’ approach. N Engl J Med. 2004;351:23842391.
Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A, Louis P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol. 2001;80:715.
Chimienti M, Cullen MT, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Eur Heart J. 1995; 16: 1943-51.
Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011; 13: 329-45.
Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380: 238-46.
Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm a(er cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD005049. DOI: 10.1002/14651858.CD005049.pub5.
Supraventricular arrhythmias, part I: premature beats and paroxysmal supraventricular tachycardias [Internet]. [cited 2023 May 25]; Available from: https://thoracickey.com/supraventricular-arrhythmias-part-i-premature-beats-and-paroxysmal-supraventricular-tachycardias/
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020; 41: 655-720.
Pre-excitation, atrioventricular reentrant (reentry) tachycardia (AVRT), Wolff-Parkinson-White (WPW) syndrome [Internet]. [cited 25 May 2023]; Available from: https://ecgwaves.com/topic/pre-excitation-avrt-wolff-parkinson-white-wpw-syndrome/
Gatzoulis K, Archontakis S, Dilaveris P, Tsiachris D. Ventricular arrhythmias: from the electrophysiology laboratory to clinical practice part I: malignant ventricular arrhythmias. Hellenic J Cardiol. 2011; 52: 525-35.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43: 3997-4126.
Gill JS, Mehta D, Ward DE, Camm J. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992; 58: 392-7.
Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol. 1984; 53: 72B-8B.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Lyon Clement
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
